Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CombiMatrix to Webcast Presentation at the UBS 2004 Global Life Sciences Conference.


NEWPORT BEACH, Calif. -- Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting
ACTG AIDS Clinical Trial Group
ACTG Actuating/Actuator
) announced today that Dr. Amit Kumar, President and Chief Executive Officer of CombiMatrix, will provide a company overview at the UBS UBS Union Bank of Switzerland
UBS United Bible Societies
UBS United Blood Services
UBS United Buying Service
UBS Used Bookstore
UBS University Business Services
UBS Universal Building Society (UK)
UBS Ulaanbaatar Broadcasting System
 2004 Global Life Sciences Conference, to be held September 28, 2004 at the Grand Hyatt Hotel in New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
.

A live transmission of the presentation will take place at 7:30 AM (PST PST Paroxysmal supraventricular tachycardia, see there ) / 10:30 AM (EST EST electroshock therapy.

EST
abbr.
electroshock therapy
) on Tuesday, September 28, 2004. An archived webcast will be available for 90 days. To access the live webcast or archived presentation, please go to www.combimatrix.com/news_events.htm.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid.
DNA
 or deoxyribonucleic acid

One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes.
 synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical im·mu·no·chem·is·try  
n.
The chemistry of immunologic phenomena, as of antigen-antibody reactions.



im
 detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand. CombiMatrix's Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia's DMT See DSL. (R) technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems. Acacia's Internet Access Redirection ("IAR IAR - Instruction Address Register.

The IBM name for program counter.
") technology covers redirected Internet registrations commonly used at wireless hotspots and hotels.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 21, 2004
Words:505
Previous Article:Toshiba Introduces Industry's Fastest Double-Layer, Dual-Format DVD Recordable Drive.
Next Article:'Bots for Business: IMlogic Pushes Instant Messaging Beyond Chat.



Related Articles
CombiMatrix Presentation at UBS Warburg Conference Available Via Telephone.
Acorda Therapeutics to Present at UBS Warburg Life Sciences Conference.
CombiMatrix to Present at the UBS Warburg Global Life Sciences Conference.
Orphan Medical to Present at the UBS Global Life Sciences Conference.
Elusys Therapeutics to Present at UBS Warburg Global Life Sciences Conference on September 24, 2003.
CombiMatrix to Webcast Dr. Amit Kumar's Presentation at UBS Global Life Science Conference.
ICOS to Participate in Three Upcoming Healthcare Conferences.
MacroPore Biosurgery to Present at the UBS Global Life Sciences Conference.
MGI PHARMA to Present at the 2004 UBS Global Life Sciences Conference.
Geron Corporation to Present at UBS Global Life Sciences Conference.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles